OVID · Ovid Therapeutics Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.58M | $7.25M | $566K | $392K | $1.5M | $208.38M | $12.62M | — | — | — | — | — | |
| $33.6M | $25.58M | $36.77M | $28.59M | $24.62M | $46.94M | $63.42M | $42.16M | $33.79M | $49.97M | $9.59M | $6.61M | |
| $26.35M | $24.11M | $25.68M | $31.09M | $32.43M | $37.23M | $30.63M | $19.25M | $19.14M | $15.04M | $12.95M | $6.58M | |
| $9000 | $100K | $200K | $100K | $193.33K | $160.21K | $247K | $216K | $106K | $53.39K | $40.22K | $7875 | |
| — | $273K | $613K | $568K | $512.51K | $237.08K | $306.85K | $255K | $141.73K | $80.31K | $56.51K | $11.78K | |
| $59.94M | $49.69M | $62.45M | $59.67M | $57.05M | $84.17M | $94.05M | $61.41M | $52.93M | $65.01M | $22.54M | $13.19M | |
| -$58.36M | -$42.44M | -$61.89M | -$59.28M | -$55.55M | $124.21M | -$81.43M | -$61.41M | -$52.93M | -$65.01M | -$22.54M | -$13.19M | |
| — | -585.2% | -10933.75% | -15122.7% | -3696.44% | 59.61% | -645.4% | — | — | — | — | — | |
| — | -$42.17M | -$61.27M | -$58.71M | -$55.04M | $124.45M | -$81.12M | -$61.15M | -$52.79M | -$64.93M | -$22.48M | -$13.18M | |
| $3.45M | $2.03M | $3.92M | $4.94M | — | — | — | — | — | — | — | — | |
| $23.87M | $25.03M | $35.45M | $6.94M | $1.38M | -$45.69K | — | $948.22K | $952.07K | $201.51K | $120.82K | $30.28K | |
| -$34.49M | -$17.41M | -$26.43M | -$52.34M | -$54.17M | $124.16M | -$81.04M | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | $0 | $1.33M | $0 | $0 | $0 | $0 | — | — | |
| -$34.49M | -$17.41M | -$26.43M | -$52.34M | -$54.17M | $122.83M | -$81.04M | -$60.46M | -$51.98M | -$64.81M | -$22.41M | -$13.16M | |
| — | -240.13% | -4670.14% | -13351.79% | -3604.66% | 58.95% | -642.26% | — | — | — | — | — | |
| -$32.65M | — | — | -$52.34M | -$54.17M | $119.84M | -$81.04M | -$60.46M | -$51.98M | -$64.81M | -$22.41M | -$13.16M | |
| -$35.18M | -$17.58M | -$26.47M | -$52.34M | -$54.21M | $122.83M | -$81.04M | -$60.46M | -$51.98M | -$64.81M | — | — | |
| USD/shares | — | — | — | -$0.74 | -$0.77 | $1.78 | -$1.39 | — | — | — | — | — |
| USD/shares | — | — | — | -$0.74 | -$0.77 | $1.76 | -$1.39 | — | — | — | — | — |
| shares | — | — | — | 70.58M | 70.42M | 67.48M | 58.45M | — | 24.63M | 19.34M | 9.84M | 9.7M |
| shares | — | — | — | 70.58M | 70.42M | 68.07M | 58.45M | — | 24.63M | 19.34M | 9.84M | 9.7M |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 318 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $7,252,000 | $566,000 | $392,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Royalty License and Termination Agreement | $230,700,000 | $223,500,000 | — | — | — |
| Related Party | — | — | $0 | $196,000,000 | $0 |
| License | — | — | $1,502,748 | $12,382,779 | $12,617,221 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -$42,439,000 | -$61,885,000 | -$59,281,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | -585.2% | -10933.7% | -15122.7% |